AFR today on MAH regarding take over:"“That’s something we’re prepared for if it happens, but it would be a shame for existing shareholders at the moment because clearly we’re undervalued,” he said."
NTI Neurotech knocked back by FDA as agency declares target condition not rare enough for special status
